Sagent raises $30 million
This article was originally published in Scrip
Sagent Pharmaceuticals has closed a $30 million extension of last year's $53 million series A financing, led by Vivo Ventures. Jeffrey Gordon, CEO, founder and board chairman, said the money would be used to advance additional products to market, as well as funding product development activities and business initiatives. In May, Sagent bought Spectrum Pharmaceuticals' US ANDA for ondansetron, for the treatment of nausea and vomiting, and the antineoplastics carboplatin, fludarabine and mitoxantrone (Scrip Online, May 14th, 2008). Privately held Sagent was founded in 2006 and has more than 200 products in development.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.